Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.89−1.96 (-4.18%)
Close on Nov 18, 2026Market cap $3.29BP/E –Yield –
Enliven Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Enliven Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$66.94M. For fiscal 2025 it was -$70.30M. The highest annual figure on record is -$21.88M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$70.30M | – |
| FY2024 | Dec 31, 2024 | -$73.19M | – |
| FY2023 | Dec 31, 2023 | -$61.27M | – |
| FY2022 | Dec 31, 2022 | -$32.08M | – |
| FY2021 | Dec 31, 2021 | -$46.77M | – |
| FY2020 | Dec 31, 2020 | -$37.40M | – |
| FY2019 | Dec 31, 2019 | -$21.88M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.29M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.48M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.89M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.84M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.15M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.45M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.36M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.49M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.90M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.37M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.02M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.35M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.53M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.04M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.15M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.41M | – |
See a number that looks wrong?